Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series

CDC. Overdose Deaths In 2021 Increased Half as Much as in 2020 - But Are Still Up 15% Web2022. 2022. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/202205.htm.

Case A, Deaton A. Deaths of despair and the future of capitalism. Princeton: Princeton University Press; 2020. p. 312.

Book  Google Scholar 

Hedegaard H, Minino AM, Spencer MR, Warner M. Drug overdose deaths in the United States, 1999–2020. NCHS Data Brief. 2021;426:1–8.

Google Scholar 

Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med. 2014;174(8):1369–76.

Article  PubMed  PubMed Central  Google Scholar 

Naeger S, Mutter R, Ali MM, Mark T, Hughey L. Post-discharge treatment engagement among patients with an opioid-use disorder. J Subst Abuse Treat. 2016;69:64–71.

Article  PubMed  Google Scholar 

Rosenthal ES, Karchmer AW, Theisen-Toupal J, Castillo RA, Rowley CF. Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis. Am J Med. 2016;129(5):481–5.

Article  PubMed  Google Scholar 

Shanahan CW, Beers D, Alford DP, Brigandi E, Samet JH. A transitional opioid program to engage hospitalized drug users. J Gen Intern Med. 2010;25(8):803–8.

Article  PubMed  PubMed Central  Google Scholar 

Trowbridge P, Weinstein ZM, Kerensky T, Roy P, Regan D, Samet JH, et al. Addiction consultation services—linking hospitalized patients to outpatient addiction treatment. J Subst Abuse Treat. 2017;79:1–5.

Article  PubMed  PubMed Central  Google Scholar 

Christian N, Bottner R, Baysinger A, Boulton A, Walker B, Valencia V, et al. Hospital buprenorphine program for opioid use disorder is associated with increased inpatient and outpatient addiction treatment. J Hosp Med. 2021;16(6):345–8.

Article  PubMed  PubMed Central  Google Scholar 

Thakrar AP, Furfaro D, Keller S, Graddy R, Buresh M, Feldman L. A resident-led intervention to increase initiation of buprenorphine maintenance for hospitalized patients with opioid use disorder. J Hosp Med. 2021;16(6):339–44.

Article  PubMed  PubMed Central  Google Scholar 

Englander H, Dobbertin K, Lind BK, Nicolaidis C, Graven P, Dorfman C, et al. Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis. J Gen Intern Med. 2019;34(12):2796–803.

Article  PubMed  PubMed Central  Google Scholar 

Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–45.

Article  PubMed  PubMed Central  Google Scholar 

Pearce LA, Min JE, Piske M, Zhou H, Homayra F, Slaunwhite A, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;368: m772.

Article  PubMed  PubMed Central  Google Scholar 

Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(9):979–93.

Article  Google Scholar 

Dupouy J, Palmaro A, Fatséas M, Auriacombe M, Micallef J, Oustric S, et al. mortality associated with time in and out of buprenorphine treatment in French Office-based general practice: a 7-year cohort study. Ann Fam Med. 2017;15(4):355–8.

Article  PubMed  PubMed Central  Google Scholar 

Lanham HJ, Papac J, Olmos DI, Heydemann EL, Simonetti N, Schmidt S, et al. Survey of barriers and facilitators to prescribing buprenorphine and clinician perceptions on the drug addiction treatment act of 2000 Waiver. JAMA Netw Open. 2022;5(5): e2212419.

Article  PubMed  PubMed Central  Google Scholar 

Lowenstein M, Kilaru A, Perrone J, Hemmons J, Abdel-Rahman D, Meisel ZF, et al. Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey. Am J Emerg Med. 2019;37(9):1787–90.

Article  PubMed  PubMed Central  Google Scholar 

National Academies of Sciences Engineering and Medicine (U.S.). Committee on Medication-Assisted Treatment for Opioid Use Disorder, Leshner AI, Mancher M, National Academies of Sciences Engineering and Medicine (U.S.). Board on Health Sciences Policy., National Academies of Sciences Engineering and Medicine (U.S.). Health and Medicine Division. Medications for opioid use disorder save lives. Washington, DC: The National Academies Press; 2019. xviii, 156 pages p.

Weber E. Failure of physicians to prescribe pharmacotherapies for addiction: regulatory restrictions and physician resistance. J Health Care Law Policy. 2010;13(1):49.

Google Scholar 

Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020. https://doi.org/10.31478/202004b.

Article  PubMed  PubMed Central  Google Scholar 

Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336–40.

PubMed  Google Scholar 

Netherland J, Botsko M, Egan JE, Saxon AJ, Cunningham CO, Finkelstein R, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244–51.

Article  PubMed  Google Scholar 

Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36(6):584–9.

Article  PubMed  PubMed Central  Google Scholar 

Rosen K, Gutierrez A, Haller D, Potter JS. Sublingual buprenorphine for chronic pain: a survey of clinician prescribing practices. Clin J Pain. 2014;30(4):295–300.

Article  PubMed  PubMed Central  Google Scholar 

Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–2.

Article  PubMed  PubMed Central  Google Scholar 

Wakeman SE, Pham-Kanter G, Donelan K. Attitudes, practices, and preparedness to care for patients with substance use disorder: results from a survey of general internists. Subst Abuse. 2016;37(4):635–41.

Article  Google Scholar 

Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunn KE, Weerts EM, Huhn AS, Schroeder JR, Tompkins DA, Bigelow GE, et al. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. Addict Biol. 2020;25(1): e12680.

Article  PubMed  Google Scholar 

Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39(1):51–7.

Article  PubMed  PubMed Central  Google Scholar 

Henoch I, Sawatzky R, Falk H, Fridh I, Jakobsson Ung E, Sarenmalm EK, et al. Symptom distress profiles in hospitalized patients in Sweden: a cross-sectional study. Res Nurs Health. 2014;37(6):512–23.

Article  PubMed  Google Scholar 

Wadensten B, Fröjd C, Swenne CL, Gordh T, Gunningberg L. Why is pain still not being assessed adequately? Results of a pain prevalence study in a university hospital in Sweden. J Clin Nurs. 2011;20(5–6):624–34.

Article  PubMed  Google Scholar 

Herzig SJ, Rothberg MB, Cheung M, Ngo LH, Marcantonio ER. Opioid utilization and opioid-related adverse events in nonsurgical patients in US hospitals. J Hosp Med. 2014;9(2):73–81.

Article  PubMed  Google Scholar 

De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425–36.

Article  PubMed  PubMed Central  Google Scholar 

Moe J, O’Sullivan F, Hohl CM, Doyle-Waters MM, Ronsley C, Cho R, et al. Systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addict Behav. 2021;114: 106740.

Article  PubMed  Google Scholar 

Becker WC, Frank JW, Edens EL. Switching from high-dose, long-term opioids to buprenorphine: a case series. Ann Intern Med. 2020;173(1):70–1.

Article  PubMed  Google Scholar 

Brar R, Fairbairn N, Sutherland C, Nolan S. Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing—a case series. Drug Alcohol Rev. 2020;39(5):588–94.

Article  PubMed  PubMed Central  Google Scholar 

Button D, Hartley J, Robbins J, Levander XA, Smith NJ, Englander H. Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis. J Addict Med. 2022;16(2):e105–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Crane K, Snead J, Stanley R, Avery J, Ghosh SM, Mints G. Intravenous buprenorphine micro-dosing induction in a patient on methadone treatment: a case report. J Acad Consult Liaison Psychiatry. 2021;62(2):243–7.

Article  PubMed  PubMed Central  Google Scholar 

Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99–105.

Article  PubMed  PubMed Central  Google Scholar 

Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict. 2019;28(4):262–5.

留言 (0)

沒有登入
gif